Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566200394> ?p ?o ?g. }
- W1566200394 abstract "Background Prevention of cognitive impairment and dementia is an important public health goal. Epidemiological evidence shows a relationship between cognitive impairment and Type 2 diabetes mellitus. The risk of dementia increases with duration of disease. This updated systematic review investigated the effect on cognitive function of the type of treatment and level of metabolic control in people with Type 2 diabetes. Objectives To assess the effects of different strategies for managing Type 2 diabetes mellitus on cognitive function and the incidence of dementia. Search methods We searched ALOIS (the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG)), the Cochrane Library, MEDLINE, Embase, PsycINFO, CINAHL and LILACS on 15 October 2016. ALOIS contains records from all major health care databases, (CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, LILACS), as well as from many trials' registers and grey literature sources. Selection criteria We included randomised controlled trials (RCTs) which compared two or more different treatments for Type 2 diabetes mellitus and in which cognitive function was measured at baseline and after treatment. Data collection and analysis Two review authors independently extracted data and assessed the quality of the included RCTs. We pooled data for comparable trials and estimated the effects of treatment by using risk ratios (RRs) and mean differences (MDs), according to the nature of the outcome. We assessed the quality of the evidence using GRADE methods. Main results We identified seven eligible studies but only four provided data we could include in efficacy analyses. Two of these studies compared intensive versus standard glycaemic control and two compared different pharmacological treatments. All studies were at unclear risk of bias in at least two domains and one large study was at high risk of performance and detection bias. (a) Two studies with 13,934 participants at high cardiovascular risk provided efficacy data on intensive versus standard glycaemic control. A third study with 1791 participants provided additional data on hypoglycaemic episodes and mortality. There is probably no difference between treatment groups in the number of participants who decline by at least 3 points on the Mini–Mental State Examination (MMSE) over five years (RR 0.98, 95% CI 0.88 to 1.08; 1 study; n = 11,140; moderate‐quality evidence); and there may also be little or no difference in the incidence of dementia (RR 1.27, 95% CI 0.87 to 1.85; 1 study; n = 11,140; low‐quality evidence). From another study, there was probably little or no difference in MMSE score after 40 months (MD −0.01, 95% CI −0.18 to 0.16; 1 study; n = 2794; moderate quality evidence). Participants exposed to the intensive glycaemic control strategy probably experience more episodes of severe hypoglycaemia than those who have standard treatment (RR 2.18, 95% CI 1.52 to 3.14; 2 studies; n = 12,827; moderate‐quality evidence). The evidence from these trials suggests that the intensity of glycaemic control may have little or no effect on all‐cause mortality (RR 0.99, 95% CI 0.87 to 1.13; 3 studies; n = 15,888; low‐quality evidence). (b) One study with 156 participants compared glibenclamide (glyburide) with repaglinide. There may be a small advantage of glibenclamide on global cognitive function measured with the MMSE after 12 months (MD −0.90, 95% CI −1.68 to −0.12; low‐quality evidence). No data were reported on the incidence of dementia, hypoglycaemic events or all‐cause mortality. (c) One study with 145 participants compared rosiglitazone plus metformin to glibenclamide (glyburide) plus metformin over 24 weeks. It reported only on cognitive subdomains and not on global cognitive function, incidence of MCI or dementia, hypoglycaemic events or all causes of mortality. Authors' conclusions We found no good evidence that any specific treatment or treatment strategy for Type 2 diabetes can prevent or delay cognitive impairment. The best available evidence related to the comparison of intensive with standard glycaemic control strategies. Here there was moderate‐quality evidence that the strategies do not differ in their effect on global cognitive functioning over 40 to 60 months." @default.
- W1566200394 created "2016-06-24" @default.
- W1566200394 creator A5030406339 @default.
- W1566200394 creator A5033402992 @default.
- W1566200394 creator A5060457132 @default.
- W1566200394 creator A5091860775 @default.
- W1566200394 date "2017-06-15" @default.
- W1566200394 modified "2023-10-17" @default.
- W1566200394 title "Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia" @default.
- W1566200394 cites W1566200394 @default.
- W1566200394 cites W1571333537 @default.
- W1566200394 cites W1590528461 @default.
- W1566200394 cites W1593393815 @default.
- W1566200394 cites W165619514 @default.
- W1566200394 cites W1667785778 @default.
- W1566200394 cites W181547059 @default.
- W1566200394 cites W1950681433 @default.
- W1566200394 cites W1968043077 @default.
- W1566200394 cites W1988761237 @default.
- W1566200394 cites W2002257186 @default.
- W1566200394 cites W2006932083 @default.
- W1566200394 cites W2014788105 @default.
- W1566200394 cites W2019307564 @default.
- W1566200394 cites W2021446295 @default.
- W1566200394 cites W2038127129 @default.
- W1566200394 cites W2046949772 @default.
- W1566200394 cites W2047474181 @default.
- W1566200394 cites W2049747547 @default.
- W1566200394 cites W2050970964 @default.
- W1566200394 cites W2057042201 @default.
- W1566200394 cites W2065012668 @default.
- W1566200394 cites W2069494503 @default.
- W1566200394 cites W2070883886 @default.
- W1566200394 cites W2071051054 @default.
- W1566200394 cites W2075319693 @default.
- W1566200394 cites W2076804918 @default.
- W1566200394 cites W2082123487 @default.
- W1566200394 cites W2093445152 @default.
- W1566200394 cites W2096418171 @default.
- W1566200394 cites W2096864643 @default.
- W1566200394 cites W2097341069 @default.
- W1566200394 cites W2110142974 @default.
- W1566200394 cites W2122522567 @default.
- W1566200394 cites W2133596089 @default.
- W1566200394 cites W2135148756 @default.
- W1566200394 cites W2135599635 @default.
- W1566200394 cites W2138030160 @default.
- W1566200394 cites W2145123193 @default.
- W1566200394 cites W2150294937 @default.
- W1566200394 cites W2151511791 @default.
- W1566200394 cites W2152471765 @default.
- W1566200394 cites W2153399820 @default.
- W1566200394 cites W2153841141 @default.
- W1566200394 cites W2155044939 @default.
- W1566200394 cites W2158446662 @default.
- W1566200394 cites W2158666727 @default.
- W1566200394 cites W2165010366 @default.
- W1566200394 cites W2165563030 @default.
- W1566200394 cites W2168866787 @default.
- W1566200394 cites W2170686624 @default.
- W1566200394 cites W2171560091 @default.
- W1566200394 cites W2188727860 @default.
- W1566200394 cites W2196549159 @default.
- W1566200394 cites W2209976199 @default.
- W1566200394 cites W2257575319 @default.
- W1566200394 cites W2328311494 @default.
- W1566200394 cites W2329872997 @default.
- W1566200394 cites W2405504823 @default.
- W1566200394 cites W2409987031 @default.
- W1566200394 cites W2470600726 @default.
- W1566200394 cites W2474778723 @default.
- W1566200394 cites W2515704584 @default.
- W1566200394 cites W2917198334 @default.
- W1566200394 cites W4211018280 @default.
- W1566200394 cites W4212929213 @default.
- W1566200394 cites W4213210402 @default.
- W1566200394 cites W4214911496 @default.
- W1566200394 cites W4242844849 @default.
- W1566200394 cites W4247665917 @default.
- W1566200394 cites W4253271202 @default.
- W1566200394 cites W4256293032 @default.
- W1566200394 cites W4301170436 @default.
- W1566200394 doi "https://doi.org/10.1002/14651858.cd003804.pub2" @default.
- W1566200394 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6481422" @default.
- W1566200394 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28617932" @default.
- W1566200394 hasPublicationYear "2017" @default.
- W1566200394 type Work @default.
- W1566200394 sameAs 1566200394 @default.
- W1566200394 citedByCount "113" @default.
- W1566200394 countsByYear W15662003942012 @default.
- W1566200394 countsByYear W15662003942013 @default.
- W1566200394 countsByYear W15662003942014 @default.
- W1566200394 countsByYear W15662003942015 @default.
- W1566200394 countsByYear W15662003942016 @default.
- W1566200394 countsByYear W15662003942017 @default.
- W1566200394 countsByYear W15662003942018 @default.
- W1566200394 countsByYear W15662003942019 @default.
- W1566200394 countsByYear W15662003942020 @default.
- W1566200394 countsByYear W15662003942021 @default.
- W1566200394 countsByYear W15662003942022 @default.